Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma

American Journal of Clinical Pathology

Volumn 110, Issue 4, 1998, Pages 443-449

  Keshgegian, Albert A ^a   Johnston, Elaine ^a   Cnaan, Avital ^b  

^a BRYN MAWR HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cell proliferation; Oncoproteins; Prognostic factors; Prostate cancer

Indexed keywords

KI 67 ANTIGEN; ONCOPROTEIN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CELL PROLIFERATION; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SEMINAL VESICLE; TUMOR SUPPRESSOR GENE;

EID: 0031667532     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/110.4.443     Document Type: Article

References (38)

1. Foster CS, Mostofi FK. Prostate cancer: present status. Hum Pathol. 1992;23:209-210.
2. Epstein JI. Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the prostate: prognostic influences of stage, tumor volume, grade and margins of resection. Semin Oncol. 1994;21:527-541.
3. Shankey TV, Kallioniemi O-P, Koslowski JM, et al. Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cytometry. 1993;14:497-500.
4. Visakorpi T. Prolifcrative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. J Pathol. 1992;168:7-13.
5. Chiusa L, Galliano D, Formiconi A, et al. High and low risk prostate carcinoma determined by histologic grade and proliferative activity. Cancer. 1997;79:1956-1963.
6. Bubendorf L, Sauter G, Moch H, et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol. 1996;178:437-441.
7. Stattin P, Damber JE, Karlberg L, et al. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol. 1997;157:219-222.
8. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 1996;156:1064-1068.
9. Levine AJ. The p53 tumor-suppressor gene. N Engl J Med. 1992;326:1350-1352.
10. Visakorpi, T Kallioniemi OP, Heikkinen A, et al. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst. 1992;84:883-887.
11. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol. 1995;26:106-109.
12. Theodorescu D, Broder SR, Boyd JC, et al. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol. 1997;158:131-137.
13. Lu QL, Abel P, Foster CS, et al. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol. 1996;27:102-110.
14. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992;52:6940-0944.
15. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993;143: 390-400.
16. Bubendorf L, Sauter G, Moch H, et al. Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol. 1996;148:1557-1565.
17. Stattin P, Damber JE, Karlberg L, et al. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol Res. 1996;24:257-264.
18. Gallie BL. Retinoblastoma gene mutations in human cancer. N Engl J Med. 1994;330:786-787.
19. Ittmann MM, Wieczorek R. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol. 1996;27:28-34.
20. INK4B gene alterations with immunohistochemical studies in human prostate carcinomas. Int J Oncol. 1996;8:107-112.
21. Gleason DF. Histologic grading and clinical staging of carcinoma of the prostate. In: Tannenbaum M, ed. Urologic Pathology: The Prostate. Philadelphia, Pa: Lea and Febiger; 1977:171-197.
22. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma: mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67, and MIB-1. Am J Clin Pathol. 1995;104:42-49.
23. Cher ML, Chew K, Rosenau W, et al. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate. 1995;26:87-93.
24. Brown C, Sauvageot J, Kahane H, et al. Cell proliferation and apoptosis in prostate cancer: correlation with pathologic stage? Mod Pathol. 1996;9:205-209.
25. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 1996;148:1567-1576.
26. Apakama I, Robinson MC, Walter NM, et al. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer. 1996;74:1258-1262.
27. Grignon DJ, Caplan R, Sarkar FH, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst. 1997;89: 158-165.
28. Henke RP, Kruger E, Ayhan N, et al. Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol. 1994;152:1297-1301.
29. Kallakury BVS, Figge J, Ross JS, et al. Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol. 1994;25:92-97.
30. Heidenberg HB, Sesterhenn IA, Gaddipati JP, et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol. 1995;154: 414-421.
31. Tamboli P, Amin MB, Hu SX, et al. Immunohistologic detection of p53 and retinoblastoma tumor suppressor gene mutations in high grade prostatic intraepithelial neoplasia (PIN) and concurrent carcinoma. Lab Invest. 1995;72:84A. Abstract.
32. Troncoso P, Pisters LL, Xu HJ, e al. Retinoblastoma gene (RB) protein expression in prostate carcinoma. Lab Invest. 1995;72:84A. Abstract.
33. Kallakury BVS, Figge J, Leibovich B, et al. Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 Kb major breakpoint region or with p53 protein accumulation. Mod Pathol. 1996;9:41-47.
34. Vesalainen SLB, Lipponen PK, Taija MT, et al. Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma. Int J Cancer. 1994;58:303-308.
35. Fox SB, Persad RA, Royds J, et al. p53 and c-myc expression in stage A1 prostatic adenocarcinoma: useful prognostic determinants? J Urol. 1993;150:490-494.
36. Bookstein R, MacGrogan D, Hilsenbeck SG, et al. p53 is mutated in a subset of advanced prostate cancers. Cancer Res. 1993;53:3369-3373.
37. Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst. 1993;85:1657-1669.
38. Mirchandani D, Zheng J, Miller GJ, et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol. 1995;147:92-101.